

ReGen Therapeutics Plc

FOR IMMEDIATE RELEASE - 20 November 2007

Results of Extraordinary General Meeting

ReGen Therapeutics Plc (the “Company”) announces that, at the Extraordinary General Meeting of the Company held earlier today, Shareholders passed all the resolutions including the resolution relating to the proposed share capital consolidation of the Company, as detailed in the circular sent to Shareholders dated 26 October 2007 (the “**Capital Consolidation**”).

To effect the Capital Consolidation it was necessary for the Company to issue an additional 90 Existing Ordinary Shares so that all fractional entitlements can be aggregated into the New Ordinary Shares. Accordingly the Company’s current issued share capital is 1,025,887,800 ordinary shares.

The expected timetable for the Capital Consolidation is as follows:

Record Date for Capital Consolidation: 6.00 p.m. on 20 November 2007

Commencement of Dealings in New Ordinary Shares 8.00 a.m. on 21 November 2007

CREST Accounts credited with New Ordinary Shares 21 November 2007

Despatch of certificates for New Ordinary Shares by 27 November 2007

Application has been made to the London Stock Exchange for the 10,258,878 New Ordinary Shares arising on the Capital Consolidation to be admitted to trading onto AIM on 21 November 2007.

Notes:

If any of the above times and/or dates change, the revised times and/or dates will be notified to Shareholders by announcement through a Regulatory Information Service.

References to time in this announcement and the Notice of Extraordinary General Meeting are to British Time.

For further enquiries:

Percy Lomax, Chairman and Chief Executive, ReGen Therapeutics Plc

Tel: 020 7153 4920

Direct: 020 8504 2156

Mobile: 07932 751541

Roland Cornish, Beaumont Cornish Limited

Tel: 020 7628 3396

Nick Bealer, King & Shaxson Capital Limited

Tel: 020 7426 5986

Andrew Marshall, Greycoat Communications

Tel: 020 7960 6007

Mobile: 07785 297111